Panacea Biotec arm gets 8 USFDA observations for Baddi facility

Published On 2022-06-11 11:45 GMT   |   Update On 2022-06-11 13:20 GMT
Advertisement

Punjab: Panacea Biotec has recently announced that its material wholly-owned subsidiary, Panacea Biotec Pharma Limited ("PBPL") has received eight observations from United States Food and Drug Administration (USFDA) at the end of the inspection.

The inspection was held at Panacea Biotec Pharma Limited's facility at Baddi, Himachal Pradesh, India between May 30, 2022 and June 08, 2022.

"At the end of inspection, PBPL was issued a 'FDA Form 483' with eight (8) observations which are related to improvements in existing procedures and are addressable," the company stated.

Advertisement

FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

Read also: Panacea Biotec gets CDSCO nod Pentavalent vaccine for 5 deadly disease

"PBPL will respond to the USFDA within the stipulated time period and work closely with USFDA to close the said observations and the closure of Warning Letter issued by the US FDA earlier on September 24, 2020," the company added in a BSE filing.

"We are committed to patient safety and quality and take quality and compliance matters seriously and stand by our commitment to fully comply with the cGMP quality standards," Panacea further added.

Read also: Panacea Biotec, CEPI, THSTI partner to develop broadly protective Betacoronavirus vaccines

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News